Keyword: Par Pharmaceutical
Dr. Reddy's moved ahead with an "at risk" launch of Indivior's top drug, but now a court has put the rollout on hold.
Kroger and other grocery chains are suing Mylan, Teva, Endo and many other companies for an "overarching conspiracy" to artificially inflate prices.
Endo has decided the 350 jobs it whacked from its Huntsville, Alabama, manufacturing site were not enough and will close it instead.
Endo didn’t even make it to the top 20 generics companies by 2014 revenue. Then the merger with Par happened, but the joy didn’t last long; its stock started tumbling down like an avalanche, and its final 2016 financial result of $2.56 billion was less than 60% of its original expectation.
It’s a tough landscape out there for generics makers—particularly the smaller ones. And that has Impax Labs thinking it may want to get a bit bigger.
Billions in revenue from Merck's Zetia is set to be challenged as Endo on Monday launched the blockbuster’s first copycat.
Endo, which has already been dealing with “previously unanticipated headwinds,” has undertaken a massive recall of subpotent birth control pills manufactured for it by a contractor.
A shortage of an injected estrogen drug in the U.S. is falling particularly hard on transgender women who need the drug for their transition.